Pacira BioSciences (PCRX) Leases (2019 - 2026)

Pacira BioSciences' Leases history runs 8 years deep, the most recent figure standing at $39.4 million for Q1 2026.

• In Q1 2026, Leases fell 19.12% year-over-year to $39.4 million; the TTM figure through Mar 2026 stood at $39.4 million (down 19.12% YoY), while the FY2025 annual figure was $41.8 million, down 15.13% from the prior year.
• Leases was $39.4 million for Q1 2026 at Pacira BioSciences, down from $41.8 million in the prior quarter.
• In the past five years, Leases ranged from a high of $74.3 million in Q1 2022 to a low of $39.4 million in Q1 2026.
• Historically, Leases has averaged $57.9 million across 5 years, with a median of $58.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Leases climbed 1.9% in 2022, then decreased 19.33% in 2024.
• A 5-year view of Leases shows it stood at $70.9 million in 2022, then retreated by 13.91% to $61.0 million in 2023, then fell by 19.33% to $49.2 million in 2024, then dropped by 15.13% to $41.8 million in 2025, then dropped by 5.67% to $39.4 million in 2026.
• The last three Leases figures came in at $39.4 million (Q1 2026), $41.8 million (Q4 2025), and $44.3 million (Q3 2025), per Business Quant data.